Global E-Cigarette Liquid Market to Reach $37 Billion by 2028

Aug.23.2022
Global E-Cigarette Liquid Market to Reach $37 Billion by 2028
The global e-cigarette liquid market is projected to reach $3.7 billion by 2028, driven by increasing health awareness and demand for safer smoking alternatives.

Market.US has released a research report stating that the global e-cigarette e-liquid market was valued at $1.7 billion in 2020 and is expected to reach $3.7 billion by 2028. The market is projected to grow at a CAGR of 12.8% from 2021 to 2028.


An increasing number of people are turning to safer smoking alternatives as awareness regarding health issues continues to grow. Electronic cigarettes are known to contain lower levels of toxic substances, and offer various flavors such as tobacco, mint, fruit, and nut. This is expected to fuel the consumption of e-cigarette oil.


Electronic cigarettes, unlike traditional tobacco cigarettes, do not contain tobacco and do not produce tar or carbon monoxide. This makes them a safer alternative to smoking. As people become more aware of the harmful effects of smoking on their health, they are more likely to quit, leading to a positive impact on the global sales of electronic cigarettes. This is one of the many reasons why the electronic cigarette industry is thriving.


Global E-liquid Market: Driving Factors


Electronic cigarette liquid is often used as a substitute for traditional tobacco. E-cigarette liquid can be infused with many flavors, providing a fresh and enhanced taste.


Electronic cigarettes are different from traditional cigarettes in that they allow you to inhale fewer toxic substances, reducing the risk of lung disease. These factors are expected to drive growth in the global liquid market. The use of e-liquid in electronic cigarettes helps reduce environmental damage, which is why manufacturers are focusing on liquid e-cigarettes, which are becoming increasingly popular. Green e-cigarettes are an obvious trend, eliminating the environmental burden associated with handling large amounts of cigarette butts.


Furthermore, electronic cigarettes reduce the issue of deforestation and the environmental degradation caused by tobacco production. Compared to traditional smoking, electronic cigarettes provide many advantages to smokers, helping them to reduce their intake of tar and nicotine and leading many to partially or completely quit smoking. These health benefits are driving demand for liquid nicotine in the electronic cigarette market. However, government regulation of e-cigarettes as tobacco products may hinder the future growth of the global e-liquid market.


The main trend in the market: Nicotine salts.


E-cigarettes are considered safer because they do not burn tobacco or produce tar or carbon monoxide. As knowledge about e-cigarettes increases, sales have also been on the rise. This is one of the main factors driving the growth of the e-cigarette oil market. Health authorities and organizations around the world are taking measures to reduce tobacco use, including indoor smoking bans and high taxes. This has encouraged people to use e-cigarettes as a means to quit smoking and has driven market growth.


Leading manufacturers are utilizing social media to promote their products, providing customized flavors, and implementing innovative marketing strategies. Online distribution channels are also being used for e-cigarette accessories and kits. With both open and closed systems becoming increasingly popular, there is an expected increase in global demand. The research report addresses the following questions:


Who are the main players in the electronic e-liquid market? What are the main driving factors for the growth of the electronic e-liquid market? Based on what types of categories is the global electronic e-liquid market classified? What is the expected market size and growth rate of the electronic e-liquid market in the future? In 2021, which distribution channels dominate the electronic e-liquid industry? What criteria are used when selecting companies?


Click to view a sample research report.


Statement


This article is compiled from third-party information and is intended solely for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity and accuracy of the article's content. The compilation of this article is only intended for industry communication and research.


Due to the limitations of the translation ability, the translated article may not accurately reflect the original text. Please refer to the original text for accuracy.


2FIRSTS is fully aligned with the Chinese government on any domestic, Hong Kong-Macau-Taiwan-related, and foreign related statements and positions.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
A federal judge in Texas on Oct. 8 granted a joint request by the FDA and plaintiffs including Altria subsidiaries Helix Innovations and NJOY to stay litigation challenging the agency's 2021 PMTA rule. The court cited FDA's anticipated rulemaking concerning the regulation at issue. FDA announced on Sept. 28 that it intends to reassess the PMTA framework and could initiate new rulemaking to replace it. The parties must file a joint status report within 45 days and every 45 days thereafter. A motion by three Reynolds American companies to intervene remains pending.
Regulations
Oct.10
Los Angeles Cracks Down on Illicit Flavored Vapes and Counterfeit Goods: 12 Businesses Searched, 24 Arrested, Eight Truckloads Seized
Los Angeles Cracks Down on Illicit Flavored Vapes and Counterfeit Goods: 12 Businesses Searched, 24 Arrested, Eight Truckloads Seized
Los Angeles authorities searched 12 businesses and arrested 24 people during a multi-agency operation targeting illicit flavored vaping products, flavored cigarettes and counterfeit merchandise on October 22, 2026. The Los Angeles County Sheriff's Department said approximately eight tractor-trailer loads of merchandise were seized. Alleged violations involved flavored tobacco sales restrictions, tobacco licensing requirements and counterfeit trademark laws. Local, state and federal agencies participated. Authorities have not disclosed the number, brands or value of vaping products seized. Investigations remain ongoing.
Enforcement
Oct.28
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024
Sep.20
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
Imperial Brands Plans to Cut Nearly 18% of Workforce as German Plant Closure and Polish Outsourcing Drive Restructuring
Imperial Brands Plans to Cut Nearly 18% of Workforce as German Plant Closure and Polish Outsourcing Drive Restructuring
Imperial Brands disclosed on November 17, 2026, that its global manufacturing and organisational restructuring is expected to reduce between 4,200 and 4,600 roles by the end of 2030, equivalent to approximately 16%–18% of its workforce at the end of 2025. The first phase covers 2,100 roles with departures confirmed or subject to consultation, while a further 2,100–2,500 positions are expected to be eliminated by 2030. The company is proceeding with the closure of its Langenhagen factory in Germany, has sold its manufacturing facility in Taiwan, and has transferred selected finance, procurement and supply-chain operations in Poland to Capgemini. The restructuring programme is expected to cost approximately £740 million, with Imperial targeting at least £320 million in annual cost savings by 2030.
company
Nov.18
Philip Morris Loses Two European Nicotine Pouch Patents in a Month Following BAT Challenges Over Nicotine Release and Formulation Technology
Philip Morris Loses Two European Nicotine Pouch Patents in a Month Following BAT Challenges Over Nicotine Release and Formulation Technology
The European Patent Office (EPO) published an appeal decision on November 17, 2026, revoking Philip Morris Products S.A.'s European nicotine pouch patent EP 3773494, covering a formulation involving free-base nicotine, ion-exchange resin and a water content of at least 15%. The decision followed an opposition and appeal brought by British American Tobacco (BAT) entity Nicoventures Trading Limited. Philip Morris withdrew its approval of the patent text during the appeal, leading the EPO to revoke the patent. A separate European patent, EP 3809884, covering the distribution of nicotine between a pouch membrane and its internal composition, had been revoked on September 24 following a challenge from another BAT entity. The patents share a 2019 priority basis, while related European divisional applications also exist.
company
Nov.18 by 2Firsts Perspectives